AI Article Synopsis

Article Abstract

The stem cell marker CD133/prominin-1, is a pentaspan membrane glycoprotein, which has also been identified as a cancer stem cell (CSC) marker in several solid tumor types, including those of the prostate, liver, colon and brain. The function of CD133 in these tumors is still unknown. We hypothesize that the function of CD133 is correlated with the characteristics of the CD133+ CSCs and may affect the growth of the tumor cell population as a whole. In this study we used antisense oligodeoxynucleotides (ASODNs) of CD133 to knock-down (KD) CD133 expression. We showed that the CD133-KD inhibited proliferation of U251 human glioma cells, decreased the colony forming ability and altered the cell cycle distribution in Huh-7 human hepatocellular carcinoma cells. Our data suggest that CD133 may play an important functional role in the growth of these tumor cells. Moreover, this study also showed that prominin-2, another protein in the same family as CD133/prominin-1, may not have a similar function.

Download full-text PDF

Source
http://dx.doi.org/10.3892/or_00000500DOI Listing

Publication Analysis

Top Keywords

huh-7 human
8
u251 human
8
human glioma
8
glioma cells
8
stem cell
8
function cd133
8
growth tumor
8
cells
5
cd133
5
cd133/prominin-1 antisense
4

Similar Publications

The most common type of liver cancer is hepatocellular carcinoma (HCC), accounting for 75-85% of cases. Despite its associated side effects, sorafenib remains the standard treatment for HCC. Given the critical need to improve therapeutic efficacy while minimizing adverse effects, alternative drugs must be thoroughly investigated.

View Article and Find Full Text PDF

Regulatory role of lnc-MAP3K13-3:1 on miR-6894-3p and SHROOM2 in modulating cellular dynamics in hepatocellular carcinoma.

BMC Cancer

January 2025

Jiangxi Provincial Key Laboratory of Child Development and Genetics, Jiangxi Provincial Children's Hospital, No. 122 of YangMing Road, DongHu District, NanChang, 330006, China.

Background: Hepatocellular carcinoma (HCC) is a prevalent primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advancements in therapeutic strategies, the 5-year survival rate for individuals undergoing curative resection remains between 10% and 15%. Consequently, identifying molecular targets that specifically inhibit the proliferation and metastasis of HCC cells is critical for improving treatment outcomes.

View Article and Find Full Text PDF

High apolipoprotein B-containing (apoB-containing) low-density lipoproteins (LDLs) and low apoA1-containing high-density lipoproteins (HDLs) are associated with atherosclerotic cardiovascular diseases. In search of a molecular regulator that could simultaneously and reciprocally control both LDL and HDL levels, we screened a microRNA (miR) library using human hepatoma Huh-7 cells. We identified miR-541-3p that both significantly decreases apoB and increases apoA1 expression by inducing mRNA degradation of 2 different transcription factors, Znf101 and Casz1.

View Article and Find Full Text PDF

Background And Study Aims: As a novel immunotherapy, chimeric antigen receptor T (CAR-T) cell technology is successful in treating hematologic malignancies, and exhibits potential benefits in partial solid tumors. Therapies targeting one antigen have some weaknesses, and dual-targeted CAR-T cells may be a better option. Alpha-fetoprotein (AFP) and glypican-3 (GPC3) are both highly expressed in hepatocellular carcinoma (HCC) and serve as important markers.

View Article and Find Full Text PDF

Food-derived components with physiological effects have been attracting attention in recent years, and studies have comprehensively analyzed these components. In this study, we sought to identify food components with functional properties for the prevention and improvement of metabolic syndrome. We performed a luciferase reporter assay using fatty acid synthase (FAS) and low-density lipoprotein receptor (LDL) receptor gene promoters.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!